Brainstorm Cell Therapeutics Dirección
Dirección controles de criterios 1/4
El CEO de Brainstorm Cell Therapeutics' es Chaim Lebovits , nombrado en Jan 2023, tiene una permanencia de 1.42 años. compensación anual total es $1.13M, compuesta por 39.1% salario y 60.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.66% de las acciones de la empresa, por valor de $501.12K. La antigüedad media del equipo directivo y de la junta directiva es de 2.4 años y 6.3 años, respectivamente.
Información clave
Chaim Lebovits
Chief Executive Officer (CEO)
US$1.1m
Compensación total
| Porcentaje del salario del CEO | 39.1% |
| Permanencia del CEO | 1.7yrs |
| Participación del CEO | 1.5% |
| Permanencia media de la dirección | 1.7yrs |
| Promedio de permanencia en la Junta Directiva | 6.5yrs |
Actualizaciones recientes de la dirección
Recent updates
Brainstorm Cell Therapeutics: Upcoming BLA In ALS
Aug 21BrainStorm Cell Therapeutics Q2 2022 Earnings Preview
Aug 12Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?
Aug 05
Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?
Mar 22Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?
Nov 26Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMS
May 30Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Deliver On Growth Plans?
May 02BrainStorm Cell Therapeutics EPS beats by $0.07
Apr 26Who Has Been Buying Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares?
Feb 21
BrainStorm Cell Therapeutics EPS misses by $0.18
Feb 04Here's Why We're Watching Brainstorm Cell Therapeutics' (NASDAQ:BCLI) Cash Burn Situation
Jan 17BrainStorm completes dosing in Phase 2 MS Study
Dec 18BrainStorm launches NurOwn Expanded Access Program
Dec 14What Percentage Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares Do Insiders Own?
Dec 13BrainStorm's NurOwn flunks in late-stage ALS study
Nov 17Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$13m |
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$1m | US$442k | -US$17m |
| Sep 30 2023 | n/a | n/a | -US$17m |
| Jun 30 2023 | n/a | n/a | -US$22m |
| Mar 31 2023 | n/a | n/a | -US$24m |
| Dec 31 2022 | US$1m | US$500k | -US$24m |
| Sep 30 2022 | n/a | n/a | -US$25m |
| Jun 30 2022 | n/a | n/a | -US$24m |
| Mar 31 2022 | n/a | n/a | -US$23m |
| Dec 31 2021 | US$1m | US$500k | -US$24m |
| Sep 30 2021 | n/a | n/a | -US$30m |
| Jun 30 2021 | n/a | n/a | -US$29m |
| Mar 31 2021 | n/a | n/a | -US$30m |
| Dec 31 2020 | US$2m | US$500k | -US$32m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$29m |
| Mar 31 2020 | n/a | n/a | -US$26m |
| Dec 31 2019 | US$1m | US$500k | -US$23m |
| Sep 30 2019 | n/a | n/a | -US$21m |
| Jun 30 2019 | n/a | n/a | -US$18m |
| Mar 31 2019 | n/a | n/a | -US$17m |
| Dec 31 2018 | US$2m | US$500k | -US$14m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$8m |
| Mar 31 2018 | n/a | n/a | -US$5m |
| Dec 31 2017 | US$1m | US$391k | -US$5m |
Compensación vs. Mercado: La compensación total de Chaim($USD1.13M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD678.50K).
Compensación vs. Ingresos: La compensación de Chaim ha aumentado mientras la empresa no es rentable.
CEO
Chaim Lebovits (53 yo)
1.7yrs
Permanencia
US$1,128,795
Compensación
Mr. Chaim Lebovits is President & Chief Executive Officer of Brainstorm Cell Therapeutics Inc. from January 2023. Mr. Lebovits was Chief Executive Officer of Brainstorm Cell Therapeutics Inc. from April 20...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President & CEO | 1.7yrs | US$1.13m | 1.46% $ 282.8k | |
| Co-Founder & Independent Vice Chair of the Board | 20.3yrs | sin datos | 0.20% $ 37.8k | |
| Interim CFO & Controller | 11.8yrs | US$146.78k | 0.082% $ 15.8k | |
| Executive VP | 7.5yrs | US$247.06k | 0.16% $ 30.8k | |
| Executive VP & COO | less than a year | sin datos | sin datos | |
| Chief Scientific Advisor | no data | sin datos | sin datos | |
| Senior Vice President of Patient Advocacy & Government Affairs | 2.7yrs | sin datos | sin datos | |
| Executive VP & Chief Medical Officer | 1.2yrs | sin datos | 0.24% $ 46.1k | |
| Senior Vice President of Research and Development | less than a year | sin datos | sin datos |
1.7yrs
Permanencia media
54yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de BCLI no se considera experimentado ( 1.5 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder & Independent Vice Chair of the Board | 20.3yrs | sin datos | 0.20% $ 37.8k | |
| Executive VP | 10.3yrs | US$247.06k | 0.16% $ 30.8k | |
| Independent Chairman of the Board | 4.5yrs | sin datos | 0.071% $ 13.8k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Business Advisory Board | 13.5yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Business Advisory Board | 16.9yrs | sin datos | sin datos | |
| Chairman of Scientific Advisory Board | 6.5yrs | sin datos | sin datos | |
| Independent Director | 6.6yrs | US$12.50k | 0.033% $ 6.3k | |
| Member of Scientific Advisory Board | 1.7yrs | US$4.46m | sin datos | |
| Director | less than a year | US$1.01m | 0.45% $ 87.9k | |
| Independent Director | 1.3yrs | sin datos | sin datos |
6.5yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: La junta directiva de BCLI se considera experimentada (6.3 años de antigüedad promedio).